These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
382 related items for PubMed ID: 31829441
1. p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies. Singh N, Piskorz AM, Bosse T, Jimenez-Linan M, Rous B, Brenton JD, Gilks CB, Köbel M. J Pathol; 2020 Mar; 250(3):336-345. PubMed ID: 31829441 [Abstract] [Full Text] [Related]
2. Clinicopathological and molecular characterisation of 'multiple-classifier' endometrial carcinomas. León-Castillo A, Gilvazquez E, Nout R, Smit VT, McAlpine JN, McConechy M, Kommoss S, Brucker SY, Carlson JW, Epstein E, Rau TT, Soslow RA, Ganesan R, Matias-Guiu X, Oliva E, Harrison BT, Church DN, Gilks CB, Bosse T. J Pathol; 2020 Mar; 250(3):312-322. PubMed ID: 31829447 [Abstract] [Full Text] [Related]
3. Correlative Assessment of p53 Immunostaining Patterns and TP53 Mutation Status by Next-Generation Sequencing in High-Grade Endometrial Carcinomas. Matsumoto N, Manrai P, Rottmann D, Wu X, Assem H, Hui P, Buza N. Int J Gynecol Pathol; 2023 Nov 01; 42(6):567-575. PubMed ID: 36730675 [Abstract] [Full Text] [Related]
4. The Many Uses of p53 Immunohistochemistry in Gynecological Pathology: Proceedings of the ISGyP Companion Society Session at the 2020 USCAP Annual9 Meeting. Köbel M, Kang EY. Int J Gynecol Pathol; 2021 Jan 01; 40(1):32-40. PubMed ID: 33290354 [Abstract] [Full Text] [Related]
5. p53 immunohistochemistry in endometrial cancer: clinical and molecular correlates in the PORTEC-3 trial. Vermij L, Léon-Castillo A, Singh N, Powell ME, Edmondson RJ, Genestie C, Khaw P, Pyman J, McLachlin CM, Ghatage P, de Boer SM, Nijman HW, Smit VTHBM, Crosbie EJ, Leary A, Creutzberg CL, Horeweg N, Bosse T, TransPORTEC consortium. Mod Pathol; 2022 Oct 01; 35(10):1475-1483. PubMed ID: 35752743 [Abstract] [Full Text] [Related]
6. Subclonal p53 immunostaining in the diagnosis of endometrial carcinoma molecular subtype. Huvila J, Thompson EF, Vanden Broek J, Lum A, Senz J, Leung S, Gilks CB, Köbel M, McAlpine JN, Jamieson A. Histopathology; 2023 Dec 01; 83(6):880-890. PubMed ID: 37580913 [Abstract] [Full Text] [Related]
7. TP53 Mutational Spectrum in Endometrioid and Serous Endometrial Cancers. Schultheis AM, Martelotto LG, De Filippo MR, Piscuglio S, Ng CK, Hussein YR, Reis-Filho JS, Soslow RA, Weigelt B. Int J Gynecol Pathol; 2016 Jul 01; 35(4):289-300. PubMed ID: 26556035 [Abstract] [Full Text] [Related]
8. Mixed endometrial carcinomas with a "low-grade serous"-like component: a clinicopathologic, immunohistochemical, and molecular genetic study. Espinosa I, D'Angelo E, Corominas M, Gonzalez A, Prat J. Hum Pathol; 2018 Jan 01; 71():65-73. PubMed ID: 29079180 [Abstract] [Full Text] [Related]
9. Equivalent Survival of p53 Mutated Endometrial Endometrioid Carcinoma Grade 3 and Endometrial Serous Carcinoma. Brett MA, Atenafu EG, Singh N, Ghatage P, Clarke BA, Nelson GS, Bernardini MQ, Köbel M. Int J Gynecol Pathol; 2021 Mar 01; 40(2):116-123. PubMed ID: 32265358 [Abstract] [Full Text] [Related]
10. Integration of clinical sequencing and immunohistochemistry for the molecular classification of endometrial carcinoma. Rios-Doria E, Momeni-Boroujeni A, Friedman CF, Selenica P, Zhou Q, Wu M, Marra A, Leitao MM, Iasonos A, Alektiar KM, Sonoda Y, Makker V, Jewell E, Liu Y, Chi D, Zamarin D, Abu-Rustum NR, Aghajanian C, Mueller JJ, Ellenson LH, Weigelt B. Gynecol Oncol; 2023 Jul 01; 174():262-272. PubMed ID: 37245486 [Abstract] [Full Text] [Related]
11. Interpretation of somatic POLE mutations in endometrial carcinoma. León-Castillo A, Britton H, McConechy MK, McAlpine JN, Nout R, Kommoss S, Brucker SY, Carlson JW, Epstein E, Rau TT, Bosse T, Church DN, Gilks CB. J Pathol; 2020 Mar 01; 250(3):323-335. PubMed ID: 31829442 [Abstract] [Full Text] [Related]
13. Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma. Köbel M, Piskorz AM, Lee S, Lui S, LePage C, Marass F, Rosenfeld N, Mes Masson AM, Brenton JD. J Pathol Clin Res; 2016 Oct 01; 2(4):247-258. PubMed ID: 27840695 [Abstract] [Full Text] [Related]
17. p53 Immunohistochemical Staining and TP53 Gene Mutations in Endometrial Cancer: Does Null Pattern Correlate With Prognosis? Sakamoto I, Kagami K, Nozaki T, Hirotsu Y, Amemiya K, Oyama T, Omata M. Am J Surg Pathol; 2023 Oct 01; 47(10):1144-1150. PubMed ID: 37528644 [Abstract] [Full Text] [Related]
18. Variability in endometrial carcinoma pathology practice: opportunities for improvement with molecular classification. Thompson EF, Huvila J, Jamieson A, Leung S, Lum A, Offman S, Lytwyn A, Sur ML, Hoang L, Irving J, van der Westhuizen N, Morin C, Bicamumpaka C, Azordegan N, Gougeon F, Ennour-Idrissi K, Senz J, McConechy MK, Aguirre-Hernandez R, Lui V, Kuo C, Bell C, Salisbury T, Lawson J, He E, Wang S, Chiu D, Kean S, Samouëlian V, Salvador S, Gotlieb W, Helpman L, Scott S, Wohlmuth C, Vicus D, Plante M, Talhouk A, Huntsman D, Parra-Herran C, Kinloch M, Grondin K, Gilks CB, McAlpine JN, Society of Gynecologic Oncologists of Canada (CoP, Translational Research). Mod Pathol; 2022 Dec 01; 35(12):1974-1982. PubMed ID: 36241860 [Abstract] [Full Text] [Related]